-
2 Key Reasons Morgan Stanley Upgraded Alexion Pharmaceuticals
Thursday, May 25, 2017 - 10:38am | 328Read More...Analysts at Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Thursday despite the stock's 17-percent loss year to date and two management shake-ups in the past six months alone. Morgan Stanley's Matthew Harrison upgraded Alexion's stock rating from Equal Weight to Overweight...
-
Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip
Tuesday, May 9, 2017 - 9:12am | 331Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a biopharmaceutical company perhaps most known for its Soliris therapy fell more than 3 percent during Monday's trading session. Investors and traders were reacting to a Bloomberg report, which said Alexion's offices in Brazil were raided by...
-
Barron's Picks And Pans: General Motors, Hess, Biotechs And More
Sunday, February 19, 2017 - 6:15pm | 594Read More...This weekend's Barron's examines the impact that ongoing streamlining may have on one of the Big 3 automakers. Other featured articles offer a peek at the prospects for an oil company and for an automotive seating supplier. The outlook for biotechs in 2017, and one buyout...
-
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive
Monday, December 12, 2016 - 12:18pm | 360Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plunged more than 15 percent Monday morning and hit a new 52-week low of $109.80 after the company's board of directors announced CEO David Hallal will leave the company amid an ongoing audit and finance committee investigation. The company's...
-
Wild Short Interest Swings For These Three Biotech Stocks
Monday, October 12, 2015 - 3:17pm | 882Read More...Short interest changes in biotech stocks were mixed during the most recent period. Baxalta Inc (NYSE: BXLT) and Juno Therapeutics Inc (NASDAQ: JUNO) saw short interest surges in late September. Short interest in Medivation Inc (NASDAQ: MDVN) plunged during that time. With the ongoing market...
-
Here's What Canaccord Learned After Spending A Day With Synageva's Management
Thursday, May 7, 2015 - 3:30pm | 280Read More...In a report published Thursday, Canaccord Genuity analyst Adam Walsh, MD detailed a recent meeting with Synageva Biopharma Corp (NASDAQ: GEVA)'s management team and came away "more positive" on the LAL-D commercial opportunity. Separately, Synageva has announced that Alexion Pharmaceuticals, Inc. (...
-
How Wedbush Sees The Alexion–Synageva Deal
Thursday, May 7, 2015 - 9:42am | 300Read More...In a report published Wednesday, Wedbush analyst David Nierengarten, Ph.D. commented on the merger agreement whereby Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will acquire Synageva Biorpharma Corp (NASDAQ: GEVA) for $115 per share in cash and 0.6581 Alexion shares – valuing shares of Synageva at...
-
Market Wrap For May 5: Dow Erases Triple-Digit Loss, All Three Major Indices Positive
Monday, May 5, 2014 - 4:36pm | 2443Read More...U.S. stocks rose as investors found that the positives in the U.S. services sector outweighed concerns over an escalating conflict in Ukraine. The Institute for Supply Management said that its service-sector index rose to 55.2. Any reading above 50.0 indicates an expansion. Also, the index...
-
Alexion Spikes As Company Hires Goldman Sachs (ALXN)
Tuesday, July 30, 2013 - 2:52pm | 194Read More...Shares of Alexion (NASDAQ: ALXN) spiked higher when Bloomberg reported that the pharmaceutical company will be working with Goldman Sachs (NYSE: GS) on a potential takeover by Roche (OTC: RHHBY). Shares of Alexion jumped as high as $120.48, or 10.2 percent on the news. More than 2.5 million...
-
Piper Jaffray Raises Its Price Target on Alexion (ALXN)
Monday, November 22, 2010 - 9:04am | 132Read More...Piper Jaffray has raised its price target on Alexion (NASDAQ: ALXN) from $86 to $94 following ALXN presenting data on Soliris this past weekend. In a note to clients, Piper Jaffray writes, "We believe the dramatic treatment benefit removes any doubt of FDA's willingness to approve Soliris on the...
-
Alexion (ALXN) and Celgene (CELG) Ratings Discusses as Revlimid Maintenance Has Last Showing Before Approval
Tuesday, November 9, 2010 - 10:17am | 73Read More...In a Piper Jaffray research report this morning Alexion (NasdaqGS: ALXN) and Celgene (NasdaqGS: CELG) are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively. Alexion has an Overweight rating with a price target of $86. Alexion closed Monday at $72.73....
-
Alexion Pharmaceuticals Buy-Rated By Deutsche Bank
Wednesday, October 27, 2010 - 9:44am | 140Read More...On October 20th, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced positive data in a new indication for Soliris – aHUS, Deutsche Bank reports. “This is a rare disease in which the body attacks its own kidney,” Deutsche Bank writes. “Soliris reduced the need for plasma therapy, but also...
